BlossomHill Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLSM research report →
Range $35 – $40
Price Chart
About the company
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment.
- CEO
- Jing Rong Jean Cui
- IPO
- 2026
- Employees
- 69
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on BLSM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $490.89M
- P/E
- -1.78
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 5.58
- EV/EBITDA
- -8.98
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 127.76%
- ROIC
- -43.86%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-64,024,000
- Net Income
- $-60,555,000-97.3%
- EPS
- $-2.08-96.2%
- OCF Growth
- -49.4%
- FCF Growth
- -52.3%
- 52W High
- $27.99
- 52W Low
- $15.25
- 50D MA
- $19.64
- 200D MA
- $19.64
- Beta
- 0.00
- RSI (14)
- 39
- Avg Volume
- 261.23K
No earnings-call transcripts are available for BLSM yet.
- Free Float
- —
- Shares Outstanding
- 29.08M
- Float Shares
- —
Held by 32 ETFs
Biggest fund positions in BLSM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 10 | Anderson John David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLSM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BLSM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
defenseworld.net · Oct 2
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
defenseworld.net · Oct 1
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
globenewswire.com · Sep 28
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
globenewswire.com · Sep 18
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
globenewswire.com · Sep 15
BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)
defenseworld.net · Sep 9
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 3
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
globenewswire.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.